Press Releases Ascendis Pharma A/S

Equities

ASND

US04351P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
141.1 ^USD	+0.06%		+3.05%	+12.03%

10:02pm	Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M	MT
Apr. 29	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascendis Pharma A/S : Form 6-K	04:59pm	PU
Ascendis Pharma Reports First Quarter 2024 Financial Results	04:01pm	AQ
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024	Apr. 25	AQ
Ascendis Pharma - United Kingdom's MHRA Approves YORVIPATH in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	Apr. 25	AQ
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	Apr. 24	AQ
Ascendis Pharma A/S : Form 6-K	Apr. 10	PU
Ascendis Pharma A/S : Form 6-K	Mar. 27	PU
Ascendis Pharma A/S : Form 6-K	Mar. 14	PU
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024	Mar. 04	AQ
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results	Feb. 07	AQ
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 07	AQ
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024	Jan. 31	AQ
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism	Jan. 31	AQ
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors	Jan. 29	AQ
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey	Jan. 08	AQ
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries	Jan. 08	AQ
Ascendis Pharma Introduces Vision 2030	Jan. 07	AQ
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries	Jan. 07	PR
Ascendis Pharma A/S : Form 6-K	Jan. 02	PU
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ascendis Pharma A/S

Equities

ASND

US04351P1012

Press Releases

Filters